Identification of immunohistochemical factors that predict the synchronous or metachronous development of bladder tumors in patients with upper urinary tract tumors

Urologia Internationalis

Volumn 81, Issue 3, 2008, Pages 306-311

  Joung, Jae Young ^a   Yang, Seung Ok ^a   Jeong, In Gab ^a   Han, Kyung Seok ^a   Seo, Ho Kyung ^a   Chung, Jinsoo ^a   Park, Weon Seo ^a   Lee, Geon Kook ^a   Lee, Kang Hyun ^a  

^a National Cancer Center   (South Korea)

Author keywords

Bladder cancer; Ki 67; Upper urinary tract tumor

Indexed keywords

BIOLOGICAL MARKER; KI 67 ANTIGEN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADULT; AGED; ARTICLE; BLADDER TUMOR; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER STAGING; CARCINOGENESIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LAPAROSCOPIC SURGERY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MULTIVARIATE ANALYSIS; NEPHROURETERECTOMY; PREDICTOR VARIABLE; PRIORITY JOURNAL; TUMOR LOCALIZATION; TUMOR VOLUME; URINARY TRACT TUMOR;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, MULTIPLE PRIMARY; NEOPLASMS, SECOND PRIMARY; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS C-BCL-2; PTEN PHOSPHOHYDROLASE; RETINOBLASTOMA PROTEIN; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TUMOR SUPPRESSOR PROTEIN P53; URETERAL NEOPLASMS; URINARY BLADDER NEOPLASMS;

EID: 54249134852     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000151409     Document Type: Article

References (19)

1. Matsui Y, Utsunomiya N, Ichioka K, Ueda N, Yoshiura K, Terai A, Arai Y: Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tract. Urology 2005;65:279-283.
2. Palou J, Roudriguez-Rubio F, Huguet J, Segarra J, Ribal MJ, Alcaraz A, Villavicencio H: Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. J Urol 2005;174:859-861.
3. Sekin H, Fukui I, Yamada T, Kihara K, Ishizaka K, Ohshima H: Clinicopathological study of upper urinary tract tumors associated with bladder tumors. Eur Urol 1991;19:19-23.
4. Kamijima S, Tobe T, Suyama T, Ueda T, Igarashi T, Ichikawa T: The prognostic value of p53, Ki-67 and metalloproteinases MMP-2 and MMP-9 in transitional cell carcinoma of the renal pelvis and ureter. Int J Urol 2005;12:941-947.
5. Margulis V, Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y: Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res 2006;12:7369-7373.
6. Seo HK, Joung JY, Chung JS, Hwang HS, Hong EK, Lee KH: Clinical significance of p53, retinoblastoma (Rb) and PTEN expression in bladder cancer. Korean J Urol Oncol 2004;2:36-40.
7. Nakopoulou L, Vourlakou C, Zervas A, Tzonou A, Gakiopoulou H, Dimopoulos MA: The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. Hum Pathol 1998;29:146-154.
8. Vardar E, Gunlusoy B, Minareci S, Postaci H, Ayder AR: Evaluation of p53 nuclear accumulation in low- and high-grade (WHO/ ISUP classification) transitional papillary carcinomas of bladder for tumor recurrence and progression. Urol Int 2007;57:158-161.
9. Kip1 and Ki-67 expression in carcinoma of the renal pelvis and ureter. BJU Int 2000;86:14-19.
10. Tsai YS, Tzai TS, Chow NH, Wu CL: Frequency and clinicopathologic correlates of ErbB1, ErbB2, and ErbB3 immunoreactivity in urothelial tumors of upper urinary tract. Urology 2005;66:1197-1202.
11. Cheville JC, Terrell RB, Cohen MB: Use of proliferative markers Ki-67 (MIB-1) and proliferating cell nuclear antigen (PC10) in transitional cell carcinoma of the renal pelvis. Mod Pathol 1994;7:794-800.
12. Mukamel E, Simon D, Edelman A, Konichezky M, Hadar H, Servadio C: Metachronous bladder tumors in patients with upper urinary tract transitional cell carcinoma. J Surg Oncol 1994;57:187-190.
13. Hafner C, Knuechel R, Stoehr R, Hartmann A: Clonality of multifocal urothelial carcinoma: 10 years of molecular genetic studies. Int J Cancer 2002;101:1-6.
14. Takahashi T, Kakehi Y, Mistsumori K, Akao T, Terachi T, Kato T: Distinct microsatellite alterations in upper urinary tract tumors and subsequent bladder tumors. J Urol 2001;165:672-677.
15. Hafner C, Knuechel R, Zanardo L, Dietmaier W, Blaszyk H, Cheville J: Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract. Oncogene 2001;20:4910-4915.
16. Krogh J, Kvist E, Rye B: Transitional cell carcinoma of the upper urinary tract: prognosis variables and post-operative recurrences. Br J Urol 1991;67:32-36.
17. Hatch TR, Hefty TR, Barry JM: Time-related recurrence rates in patients with upper tract transitional cell carcinoma. J Urol 1998;140:40-41.
18. Hisataki T, Miyao N, Masumori N, Takahashi A, Sasai M, Yanase M, Itoh N, Tsukamoto T: Risk factors for the development of bladder cancer after upper tract urothelial cancer. Urology 2000;55:663-667.
19. Rey A, Lara PC, Redondo E, Valdes E, Apolinario R: Overexpression of p53 in transitional cell carcinoma of the renal pelvis and ureter. Relation to tumor proliferation and survival. Cancer 1997;79:2178-2185.